In a new development, the Federal Court of Appeal and Federal Court have issued three influential decisions regarding macitentan (Janssen’s OPSUMIT). The Federal Court of Appeal (FCA) has reportedly dismissed an appeal on the finding of inducement, marking a defining point for the most prominent players in the legal and pharmaceutical sectors.
In the case Apotex Inc v Janssen Inc, Apotex brought forth an appeal against the trial decision, asserting that its product, Apo-Macitentan, would infringe Canadian Patent No. 2,659,770 (770 Patent). So far, the development is not in favor of Apotex as the Federal Court of Appeal upheld the trial decision and dismissed the appeal.
The decisions in question were issued by both the Federal Court of Appeal and the Federal Court and relate to Janssen’s OPSUMIT, known medically as macitentan. Macitentan is an endothelin receptor antagonist that is routinely used for the treatment of pulmonary arterial hypertension.
The overall implications of these decisions are broad, particularly for legal professionals advising pharmaceutical firms or those directly involved in disputes relating to patent infringements. It is an understanding that the energy and resources invested in patent protection are not pointless, provided a sound and in-depth understanding of the patent landscape is realized.
For more information on this topic, access the detailed coverage here.